{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:06:47Z","timestamp":1790096807848,"version":"4.0.1"},"reference-count":110,"publisher":"Elsevier","isbn-type":[{"value":"9780443470882","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.enz.2026.03.005","type":"book-chapter","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:47:35Z","timestamp":1776340055000},"page":"317-338","source":"Crossref","is-referenced-by-count":0,"title":["Challenges and opportunities in the drug design and pharmacological applications of MMP inhibitors"],"prefix":"10.1016","author":[{"given":"Claudiu T.","family":"Supuran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0001","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/pharmrev.121.000349","article-title":"Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology","volume":"74","author":"de Almeida","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/bs.enz.2026.03.005_bib0002","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.enz.2026.03.005_bib0003","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"197","article-title":"Matrix metalloproteases","author":"Trabocchi","year":"2024"},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/ph14010031","article-title":"The pharmacological TAILS of matrix metalloproteinases and their inhibitors","volume":"14","author":"Das","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/bs.enz.2026.03.005_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tips.2013.02.004","article-title":"Missing the target: matrix metalloproteinase antitargets in inflammation and cancer","volume":"34","author":"Dufour","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/bs.enz.2026.03.005_bib0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/13543776.2021.1881481","article-title":"Novel matrix metalloproteinase inhibitors: an updated patent review (2014\u20132020)","volume":"31","author":"Lenci","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2741\/s430","article-title":"Degradomics of matrix metalloproteinases in inflammatory diseases","volume":"7","author":"Dufour","year":"2015","journal-title":"Front. Biosci."},{"issue":"10","key":"10.1016\/bs.enz.2026.03.005_bib0008","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543776.2023.2284935","article-title":"An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)","volume":"33","author":"Banerjee","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"issue":"9","key":"10.1016\/bs.enz.2026.03.005_bib0009","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1021\/cr9804543","article-title":"Design and therapeutic application of matrix metalloproteinase inhibitors","volume":"99","author":"Whittaker","year":"1999","journal-title":"Chem. Rev."},{"issue":"14","key":"10.1016\/bs.enz.2026.03.005_bib0010","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1158\/0008-5472.CAN-10-4552","article-title":"Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9","volume":"71","author":"Dufour","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/bs.enz.2026.03.005_bib0011","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.enz.2026.03.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129411","article-title":"A simple yet multifaceted 90 years old, evergreen enzyme: carbonic anhydrase, its inhibition and activation","volume":"93","author":"Supuran","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2026.03.005_bib0013","series-title":"Hydroxamic Acids: A Unique Family of Chemicals with Multiple Biological Activities","first-page":"55","article-title":"Hydroxamates as carbonic anhydrase inhibitors","author":"Supuran","year":"2013"},{"issue":"5","key":"10.1016\/bs.enz.2026.03.005_bib0014","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/biom10050717","article-title":"Challenges in matrix metalloproteinases inhibition","volume":"10","author":"Laronha","year":"2020","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/bs.enz.2026.03.005_bib0015","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1021\/jm400529f","article-title":"Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core","volume":"56","author":"Jin","year":"2013","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/bs.enz.2026.03.005_bib0016","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/cmdc.202000994","article-title":"Phosphonate as a Stable Zinc-Binding Group for \u201cpathoblocker\u201d inhibitors of clostridial collagenase H (ColH)","volume":"16","author":"Voos","year":"2021","journal-title":"ChemMedChem"},{"issue":"17","key":"10.1016\/bs.enz.2026.03.005_bib0017","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1021\/jm300981b","article-title":"Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment","volume":"55","author":"Reich","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0018","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/14756366.2017.1378192","article-title":"Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids","volume":"32","author":"Luisi","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/bs.enz.2026.03.005_bib0019","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"1","year":"2024"},{"issue":"43","key":"10.1016\/bs.enz.2026.03.005_bib0020","doi-asserted-by":"crossref","first-page":"14012","DOI":"10.1021\/bi00043a007","article-title":"Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor","volume":"34","author":"Grams","year":"1995","journal-title":"Biochemistry"},{"issue":"20","key":"10.1016\/bs.enz.2026.03.005_bib0021","doi-asserted-by":"crossref","first-page":"17405","DOI":"10.1074\/jbc.M007475200","article-title":"The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition","volume":"276","author":"Brandstetter","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/bs.enz.2026.03.005_bib0022","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3109\/14756366.2014.1000889","article-title":"Kinetic characterization of 4,4\u2032-biphenylsulfonamides as selective non-zinc binding MMP inhibitors","volume":"30","author":"Santamaria","year":"2015","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0023","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/13543776.2025.2602702","article-title":"An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease (2021-present)","volume":"36","author":"Begines","year":"2026","journal-title":"Expert Opin. Ther. Pat."},{"issue":"Suppl 2","key":"10.1016\/bs.enz.2026.03.005_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jnc.13990","article-title":"Natural genomic amplification of cholinesterase genes in animals","volume":"142","author":"Chatonnet","year":"2017","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/bs.enz.2026.03.005_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/13543776.2026.2633345","article-title":"Patents involving monoamine oxidase (MAO): a comprehensive update (2022-2025) on its inhibitors and applications","volume":"36","author":"Shaldam","year":"2026","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/bs.enz.2026.03.005_bib0026","series-title":"Metalloenzymes from Bench to Bedside","first-page":"431","article-title":"Cyclooxygenase","author":"Romanelli","year":"2024"},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.124.001125","article-title":"Multi- and polypharmacology of carbonic anhydrase inhibitors","volume":"77","author":"Supuran","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/bs.enz.2026.03.005_bib0028","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tips.2025.07.002","article-title":"Human carbonic anhydrase modulators: the past, present, and future","volume":"46","author":"Giovannuzzi","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"21","key":"10.1016\/bs.enz.2026.03.005_bib0029","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1016\/j.bmcl.2010.08.110","article-title":"Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of \u03b1- but not of \u03b2-, \u03b3- and \u03b6-carbonic anhydrases","volume":"20","author":"Innocenti","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/bs.enz.2026.03.005_bib0030","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.bmcl.2008.03.012","article-title":"Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates","volume":"18","author":"Innocenti","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0031","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/acs.chemrev.4c00278","article-title":"Multiple binding modes of inhibitors to human carbonic anhydrases: an update on the design of isoform-specific modulators of activity","volume":"125","author":"D\u2019Ambrosio","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/bs.enz.2026.03.005_bib0032","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"207","article-title":"A disintegrin and metalloproteinases (ADAMs) and tumor necrosis factor-alpha converting enzyme (TACE)","author":"Cuffaro","year":"2024"},{"issue":"10","key":"10.1016\/bs.enz.2026.03.005_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110643","article-title":"The cytoplasmic domain of the pseudoprotease iRhom2 mediates distinct signaling mechanisms to control activation of the cell surface protease ADAM17","volume":"301","author":"Lu","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0034","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12964-026-02743-0","article-title":"The ADAMTS family: from extracellular matrix proteases to orchestrators of fibrosis","volume":"24","author":"Yuan","year":"2026","journal-title":"Cell Commun. Signal."},{"issue":"20","key":"10.1016\/bs.enz.2026.03.005_bib0035","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/jm000027t","article-title":"Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes","volume":"43","author":"Scozzafava","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2026.03.005_bib0036","series-title":"Matrix Metalloproteinase Biology","first-page":"131","article-title":"Subtracting matrix out of the equation: new key roles of matrix metalloproteinases in innate immunity and disease","author":"Dufour","year":"2015"},{"key":"10.1016\/bs.enz.2026.03.005_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116152","article-title":"Discovery of matrix metalloproteinase inhibitors as anti-skin photoaging agents","volume":"267","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/bs.enz.2026.03.005_bib0038","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1167\/iovs.16-21377","article-title":"An ilomastat-CD eye drop formulation to treat ocular scarring","volume":"58","author":"Mohamed-Ahmed","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5415","key":"10.1016\/bs.enz.2026.03.005_bib0039","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.284.5415.808","article-title":"Effects of angiogenesis inhibitors on multistage carcinogenesis in mice","volume":"284","author":"Bergers","year":"1999","journal-title":"Science"},{"key":"10.1016\/bs.enz.2026.03.005_bib0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1749-6632.1999.tb07689.x","article-title":"Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials","volume":"878","author":"Shalinsky","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"12","key":"10.1016\/bs.enz.2026.03.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70178","article-title":"Current scenario of hydroxamic acid derivatives with in vivo antitumor therapeutic potential","volume":"358","author":"Xu","year":"2025","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not be the best histone deacetylase inhibitors\u2014what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.enz.2026.03.005_bib0043","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"449","article-title":"Cytochrome P450 (inhibitors for the metabolism of drugs)","author":"Akdemir","year":"2024"},{"key":"10.1016\/bs.enz.2026.03.005_bib0044","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"467","article-title":"Iron enzymes, nonheme containing","author":"Ferraroni","year":"2024"},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06587-1","article-title":"Biochemical formation and pharmacological, toxicological, and pathological properties of hydroxylamines and hydroxamic acids","volume":"25","author":"Weisburger","year":"1973","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0046","first-page":"417","article-title":"Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice","volume":"53","author":"Powell","year":"1993","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/bs.enz.2026.03.005_bib0047","first-page":"4726","article-title":"Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice","volume":"54","author":"Wang","year":"1994","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/bs.enz.2026.03.005_bib0048","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/87.20.1546","article-title":"Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice","volume":"87","author":"Sledge","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/bs.enz.2026.03.005_bib0049","first-page":"1207","article-title":"The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice","volume":"2","author":"Low","year":"1996","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/bs.enz.2026.03.005_bib0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/A:1018418725453","article-title":"Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases","volume":"15","author":"Santos","year":"1997","journal-title":"Clin. Exp. Metastasis"},{"issue":"5","key":"10.1016\/bs.enz.2026.03.005_bib0051","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2125.2006.02794.x","article-title":"Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers","volume":"63","author":"Mant","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/bs.enz.2026.03.005_bib0052","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1158\/1078-0432.CCR-06-1586","article-title":"A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors","volume":"13","author":"Chiappori","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/bs.enz.2026.03.005_bib0053","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/1078-0432.CCR-04-0804","article-title":"A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties","volume":"10","author":"Syed","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0054","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-011-0602-9","article-title":"Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas","volume":"105","author":"Rudek","year":"2011","journal-title":"J. Neurooncol."},{"issue":"4","key":"10.1016\/bs.enz.2026.03.005_bib0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10637-006-9031-6","article-title":"A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas","volume":"25","author":"Chu","year":"2007","journal-title":"Invest. New Drugs"},{"issue":"9","key":"10.1016\/bs.enz.2026.03.005_bib0056","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2005.04.2614","article-title":"Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi\u2019s sarcoma: an AIDS Malignancy Consortium Study","volume":"24","author":"Dezube","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0057","first-page":"630","article-title":"COL\u20113 enhances the anti\u2011proliferative and pro\u2011apoptotic effects of paclitaxel in breast cancer cells","volume":"41","author":"El-Tabba\u2019","year":"2019","journal-title":"Oncol. Rep."},{"issue":"12","key":"10.1016\/bs.enz.2026.03.005_bib0058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114457","article-title":"Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells","volume":"9","author":"Song","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0059","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1014546909573","article-title":"Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue","volume":"19","author":"Dupont","year":"2002","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","article-title":"Angiogenesis: regulators and clinical applications","volume":"61","author":"Liekens","year":"2001","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0061","first-page":"299","article-title":"The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model","volume":"20","author":"Weber","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/bs.enz.2026.03.005_bib0062","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0093-7754(01)90035-1","article-title":"Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials","volume":"28","author":"Falardeau","year":"2001","journal-title":"Semin Oncol."},{"issue":"12","key":"10.1016\/bs.enz.2026.03.005_bib0063","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jnci\/djq179","article-title":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial","volume":"102","author":"Lu","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/bs.enz.2026.03.005_bib0064","first-page":"618","article-title":"FDA grants orphan-drug status to Aeterna\u2019s Neovastat for kidney cancer","volume":"2","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"9","key":"10.1016\/bs.enz.2026.03.005_bib0065","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-11-4149","article-title":"Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth","volume":"72","author":"Remacle","year":"2012","journal-title":"Cancer Res."},{"issue":"38","key":"10.1016\/bs.enz.2026.03.005_bib0066","doi-asserted-by":"crossref","first-page":"33167","DOI":"10.1074\/jbc.M111.256644","article-title":"Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration","volume":"286","author":"Zarrabi","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/bs.enz.2026.03.005_bib0067","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.3390\/ijms26167956","article-title":"Inhibition of metalloproteinases-2, -9, and -14 suppresses papillary thyroid carcinoma cell migration and invasion","volume":"26","author":"Rocco","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"45","key":"10.1016\/bs.enz.2026.03.005_bib0068","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/onc.2017.219","article-title":"The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia\/MMP14-mediated invasion","volume":"36","author":"Swayampakula","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/bs.enz.2026.03.005_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113260","article-title":"Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II","volume":"214","author":"Lenci","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"40","key":"10.1016\/bs.enz.2026.03.005_bib0070","doi-asserted-by":"crossref","first-page":"33992","DOI":"10.1074\/jbc.M504303200","article-title":"Potent mechanism-based inhibitors for matrix metalloproteinases","volume":"280","author":"Ikejiri","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/bs.enz.2026.03.005_bib0071","doi-asserted-by":"crossref","first-page":"11201","DOI":"10.1074\/jbc.M111021200","article-title":"Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases","volume":"277","author":"Bernardo","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0072","doi-asserted-by":"crossref","DOI":"10.1111\/exd.70203","article-title":"Matrix metalloproteinase inhibition in melanoma","volume":"35","author":"Zhang","year":"2026","journal-title":"Exp. Dermatol."},{"issue":"7","key":"10.1016\/bs.enz.2026.03.005_bib0073","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.2003.013243","article-title":"MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis","volume":"63","author":"Tchetverikov","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/bs.enz.2026.03.005_bib0074","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2741\/1817","article-title":"Matrix metalloproteinases: role in arthritis","volume":"11","author":"Burrage","year":"2006","journal-title":"Front. Biosci."},{"issue":"6","key":"10.1016\/bs.enz.2026.03.005_bib0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-023-00966-w","article-title":"Matrix metalloproteinases in arthritis: towards precision medicine","volume":"19","author":"Grillet","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0076","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.bjp.0701150","article-title":"Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo","volume":"121","author":"Lewis","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/bs.enz.2026.03.005_bib0077","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/rheumatology\/40.5.537","article-title":"Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade\u2122 in patients with rheumatoid arthritis","volume":"40","author":"Hemmings","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/bs.enz.2026.03.005_bib0078","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/IAI.00073-14","article-title":"Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis","volume":"82","author":"Liechti","year":"2014","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0079","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40261-020-00981-9","article-title":"First-in-man safety, tolerability, and pharmacokinetics of a novel and highly selective inhibitor of matrix metalloproteinase-12, FP-025: results from two randomized studies in healthy subjects","volume":"41","author":"Abd-Elaziz","year":"2021","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0080","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/all.15513","article-title":"Efficacy of FP-025: a novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma","volume":"78","author":"Ravanetti","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/bs.enz.2026.03.005_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124244","article-title":"Validation of a method for the determination of Aderamastat (FP-025) in K2EDTA human plasma by LC-MS\/MS","volume":"1245","author":"Abd-Elaziz","year":"2024","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"8","key":"10.1016\/bs.enz.2026.03.005_bib0082","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1021\/acsinfecdis.4c00385","article-title":"Breaking the cycle: matrix metalloproteinase inhibitors as an alternative approach in managing tuberculosis pathogenesis and progression","volume":"10","author":"Jhilta","year":"2024","journal-title":"ACS Infect. Dis."},{"issue":"15","key":"10.1016\/bs.enz.2026.03.005_bib0083","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141895","article-title":"Doxycycline host-directed therapy in human pulmonary tuberculosis","volume":"131","author":"Miow","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/bs.enz.2026.03.005_bib0084","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.STR.0000083051.93319.28","article-title":"Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion","volume":"34","author":"Pfefferkorn","year":"2003","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/bs.enz.2026.03.005_bib0085","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nm1387","article-title":"Role of matrix metalloproteinases in delayed cortical responses after stroke","volume":"12","author":"Zhao","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0086","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.expneurol.2008.05.022","article-title":"Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats","volume":"213","author":"Copin","year":"2008","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0087","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nbd.2006.10.013","article-title":"Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia","volume":"25","author":"Burggraf","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0088","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.nbd.2008.12.012","article-title":"Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia","volume":"34","author":"Lee","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0089","doi-asserted-by":"crossref","first-page":"H87","DOI":"10.1152\/ajpheart.01206.2010","article-title":"Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats","volume":"301","author":"Pires","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-5-1","article-title":"Suppression of MMP-9 by doxycycline in brain arteriovenous malformations","volume":"5","author":"Hashimoto","year":"2005","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0091","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jvs.2008.09.055","article-title":"Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content","volume":"49","author":"Abdul-Hussien","year":"2009","journal-title":"J. Vasc. Surg."},{"issue":"5","key":"10.1016\/bs.enz.2026.03.005_bib0092","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00011-013-0704-2","article-title":"The effect of prolonged systemic doxycycline therapy on serum tissue degrading proteinases in coronary bypass patients: a randomized, double-masked, placebo-controlled clinical trial","volume":"63","author":"Kormi","year":"2014","journal-title":"Inflamm. Res."},{"key":"10.1016\/bs.enz.2026.03.005_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2022.104381","article-title":"Doxycycline can reduce glycocalyx shedding by inhibiting matrix metalloproteinases in patients undergoing cardiopulmonary bypass: a randomized controlled trial","volume":"142","author":"Gao","year":"2022","journal-title":"Microvasc. Res."},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0094","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1556\/EuJMI.1.2011.3.7","article-title":"Selective gelatinase blockage ameliorates acute DSS colitis","volume":"1","author":"Heimesaat","year":"2011","journal-title":"Eur. J. Microbiol. Immunol. (Bp)"},{"issue":"8","key":"10.1016\/bs.enz.2026.03.005_bib0095","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/imj.12179","article-title":"Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad","volume":"43","author":"Lee","year":"2013","journal-title":"Intern. Med. J."},{"issue":"9","key":"10.1016\/bs.enz.2026.03.005_bib0096","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ibd\/izz006","article-title":"Efficacy of combination antibiotic therapy for refractory pediatric inflammatory bowel disease","volume":"25","author":"Breton","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"8","key":"10.1016\/bs.enz.2026.03.005_bib0097","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1007\/s10620-020-06477-y","article-title":"Randomized trial of ciprofloxacin doxycycline and hydroxychloroquine versus budesonide in active Crohn\u2019s disease","volume":"66","author":"Rhodes","year":"2021","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/bs.enz.2026.03.005_bib0098","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsptsci.0c00104","article-title":"The selective MMP-9 inhibitor (R)-ND-336 alone or in combination with linezolid accelerates wound healing in infected diabetic mice","volume":"4","author":"Peng","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/bs.enz.2026.03.005_bib0099","doi-asserted-by":"crossref","first-page":"8825","DOI":"10.1021\/acs.jmedchem.8b01005","article-title":"Validation of matrix metalloproteinase-9 (MMP-9) as a novel target for treatment of diabetic foot ulcers in humans and discovery of a potent and selective small-molecule MMP-9 inhibitor that accelerates healing","volume":"61","author":"Nguyen","year":"2018","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0100","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1021\/acsptsci.1c00063","article-title":"Metabolism of the selective matrix metalloproteinase-9 inhibitor (R)-ND-336","volume":"4","author":"Gabriel","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"10","key":"10.1016\/bs.enz.2026.03.005_bib0101","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1021\/acsptsci.4c00263","article-title":"Targeting matrix metalloproteinase-9 for therapeutic intervention in diabetic foot ulcers","volume":"7","author":"Chang","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1902\/jop.2004.75.3.441","article-title":"Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial","volume":"75","author":"Gapski","year":"2004","journal-title":"J. Periodontol."},{"issue":"7","key":"10.1016\/bs.enz.2026.03.005_bib0103","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s00784-019-02915-y","article-title":"Matrix metalloproteinases and inhibitors in dentistry","volume":"23","author":"Boelen","year":"2019","journal-title":"Clin. Oral Investig."},{"issue":"5","key":"10.1016\/bs.enz.2026.03.005_bib0104","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/07853890600800103","article-title":"Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation","volume":"38","author":"Sorsa","year":"2006","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/bs.enz.2026.03.005_bib0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-051X.2008.01351.x","article-title":"Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial","volume":"36","author":"Gapski","year":"2009","journal-title":"J. Clin. Periodontol."},{"issue":"6","key":"10.1016\/bs.enz.2026.03.005_bib0106","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/antibiotics11060738","article-title":"One-year clinical, microbiological and immunological results of local doxycycline or antimicrobial photodynamic therapy for recurrent\/persisting periodontal pockets: a randomized clinical trial","volume":"11","author":"Cosgarea","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/bs.enz.2026.03.005_bib0107","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/10600280211027968","article-title":"Abametapir for the treatment of head lice: a drug review","volume":"56","author":"Woods","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"1\u20136","key":"10.1016\/bs.enz.2026.03.005_bib0108","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/ijt.ijt_77_22","article-title":"Abametapir: a new solution to an age old problem","volume":"16","author":"Chakraborty","year":"2024","journal-title":"Int. J. Trichol."},{"key":"10.1016\/bs.enz.2026.03.005_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.pestbp.2021.105013","article-title":"New chemistries for the control of human head lice, Pediculus humanus capitis: a mini-review","volume":"181","author":"Clark","year":"2022","journal-title":"Pestic. Biochem. Physiol."},{"key":"10.1016\/bs.enz.2026.03.005_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.01.019","article-title":"In vitro assessment of a combination therapy of abametapir and flavesone as a novel topical single-dose scabies treatment","author":"Fernando","year":"2026","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["The Enzymes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604726000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604726000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:10:38Z","timestamp":1790093438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604726000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470882"],"references-count":110,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2026.03.005","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}